The real-world outcome of metastatic melanoma: Unknown primary vs. known cutaneous

Eva Ellebaek; Lars Bastholt; Henrik Schmidt; Inge M Svane; Marco Donia

doi:10.1002/ijc.32631

The real-world outcome of metastatic melanoma: Unknown primary vs. known cutaneous

Eva Ellebaek, Lars Bastholt, Henrik Schmidt, Inge M Svane, Marco Donia

Publikation: Bidrag til tidsskrift › Letter › peer review

12 Citationer (Scopus)

47 Downloads (Pure)

Originalsprog	Engelsk
Tidsskrift	International Journal of Cancer
Vol/bind	145
Udgave nummer	11
Sider (fra-til)	3173-3174
Antal sider	2
ISSN	0020-7136
DOI	https://doi.org/10.1002/ijc.32631
Status	Udgivet - 1 dec. 2019

Adgang til dokumentet

10.1002/ijc.32631

The real-world outcome of metastatic melanoma (acc. manuscript)Accepteret manuskript, 277 KB

Biblioteksadgang?

Tjek tilgængelighed hos det Kgl. Bibliotek

Citationsformater

@article{6e4e9666c22f4b78aed13083db17d049,

title = "The real-world outcome of metastatic melanoma: Unknown primary vs. known cutaneous",

keywords = "Administration, Cutaneous, Humans, Immunotherapy, Melanoma, Neoplasms, Unknown Primary, Skin Neoplasms",

author = "Eva Ellebaek and Lars Bastholt and Henrik Schmidt and Svane, {Inge M} and Marco Donia",

year = "2019",

month = dec,

day = "1",

doi = "10.1002/ijc.32631",

language = "English",

volume = "145",

pages = "3173--3174",

journal = "International Journal of Cancer",

issn = "0020-7136",

publisher = "JohnWiley & Sons, Inc.",

number = "11",

}

TY - JOUR

T1 - The real-world outcome of metastatic melanoma

T2 - Unknown primary vs. known cutaneous

AU - Ellebaek, Eva

AU - Bastholt, Lars

AU - Schmidt, Henrik

AU - Svane, Inge M

AU - Donia, Marco

PY - 2019/12/1

Y1 - 2019/12/1

KW - Administration, Cutaneous

KW - Humans

KW - Immunotherapy

KW - Melanoma

KW - Neoplasms, Unknown Primary

KW - Skin Neoplasms

U2 - 10.1002/ijc.32631

DO - 10.1002/ijc.32631

M3 - Letter

C2 - 31423583

SN - 0020-7136

VL - 145

SP - 3173

EP - 3174

JO - International Journal of Cancer

JF - International Journal of Cancer

IS - 11

ER -